FENC Stock Summary and Trading Ideas (Fennec Pharmaceuticals | NASDAQ:FENC)

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals trades on the NASDAQ stock market under the symbol FENC.

As of March 6, 2026, FENC stock price declined to $7.70 with 139,588 million shares trading.

FENC has a beta of 1.59, meaning it tends to be more sensitive to market movements. FENC has a correlation of 0.32 to the broad based SPY ETF.

FENC has a market cap of $262.98 million. This is considered a Small Cap stock.

Last quarter Fennec Pharmaceuticals reported $12 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.03.

In the last 3 years, FENC traded as high as $11.92 and as low as $3.96.

The top ETF exchange traded funds that FENC belongs to (by Net Assets): VTI, IWM, IWN, VTWO, IWC.

FENC has underperformed the market in the last year with a price return of +13.1% while the SPY ETF gained +18.7%. However, in the short term, FENC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.0% vs -1.7% return in SPY. But in the last 2 weeks, FENC shares have been beat by the market, returning -11.9% compared to an SPY return of -2.5%.

FENC support price is $7.65 and resistance is $8.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FENC shares will trade within this expected range on the day.